Description:
More powerful than echinacea alone. Esberitox delivers uniquely powerful immune system support. It's different from simple single-herb echinacea products because it's made with an herbal combination that addresses a broader range of immune functions. That combination includes the key components of two echinacea extracts: Echinacea purpurea and pallida (purple coneflower), along with Thuja (white cedar), and Baptisia (wild indigo). Esberitox is especially beneficial whenever extra immune system support is desired.These tasty, chewable tablets work great for the whole family. Kids love them. A product of Germany, Esberitox's proprietary formula is now available in the United States exclusively from Enzymatic Therapy.
The Inside Scoop:
Clinically proven unique combination of herbs to promote the body's resistive functions.
Nutritionally supports and stimulates the immune system.
Nutrition Facts:
Serving Size (g) 0
Servings Per 0
Calories 0
Fat Calories 0
Total Fat (g) 0
Sat. Fat (g) 0
Cholesterol (mg) 0
Sodium (mg) 0
Potassium (mg) 0
Total Carbs (g) 0
Dietary Fiber (g) 0
Sugars (g) 0
Proteins (g) 0
Ingredient Details:
Serving Size: 3 Chewable Tablets Wild indigo (Baptisia tinctoria) 30mg Echinacea purpurea and pallida 1:1 22.5mg Thuja 6mg
Other Ingredients: lactose, sugar, macrogol, ascorbic acid, and magnesium stearate.
Contains No: salt, yeast, wheat, gluten, corn, soy, artificial coloring, artificial flavoring and preservatives. This product contains natural ingredients; color variations are normal.
Suggested Use:
Adults and children over 12 years of age, three tablets, three times per day. Ages 6-12, two tablets, three times per day. Age 2-5, one tablet, three times per day. Age 1 and younger, consult a health care practitioner before using. Tablet can be swallowed, or chewed and dissolved in mouth.
Warnings:
Not recommended for individuals with autoimmune diseases, HIV infection, progressive systemic disease, or who are allergic to echinacea or other flowers of the Compositae (or Asteraceae) family.
